2017 Fiscal Year Final Research Report
Development of comprehensive therapeutic storategies for diabetic retinopathy
| Project/Area Number |
15H04995
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
池田 康博 九州大学, 医学研究院, 准教授 (20380389)
星野 友 九州大学, 工学研究院, 准教授 (40554689)
吉田 茂生 九州大学, 大学病院, 助手 (50363370)
中尾 新太郎 九州大学, 大学病院, 講師 (50583027)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 糖尿病網膜症 / ROCK / ペリオスチン / 線維化 / 透過性 / 血管内皮細胞 |
|---|
| Outline of Final Research Achievements |
We aimed to establish a novel molecular targeting therapy based on two important pathological conditions, retinal fibrovascular memmbrane formation and macular edema in diabetic retinopathy. We have clarified the involvement of tenascin-C whose expression is specifically enhanced in retinal fibrovascular proliferation. In addition, RNAi tarageting tenascin-C showed significant inhibitory effect on retinal fibrovascular proliferation. On the other hand, inflammatory cytokine stimulation including MCP-1, IL-6, TNF-a was performed after pre-administration of ROCK-inhibitor, Lipasdir, to the cultured vascular endothelial cells. The inhibiton of ROCK pathway resulted in a decrease in transendothelial electric resistance and claudin-5 expression. These results indicated that Lipasdir may inhibit disruption of barrier function by supressing inflammatory cytokines other than VEGF.
|
| Free Research Field |
眼科学
|
